Insilico Medicine and Bora Pharma launch AI-driven biologics manufacturing venture to challenge Chinese CDMOs

Insilico Medicine, an AI drug discovery company, and Bora Pharmaceuticals, a Taiwan-based CDMO, announced the formation of a new joint venture.

The new company will develop an AI-driven platform to automate and accelerate biologics manufacturing, aiming to improve efficiency and reduce costs.

The partners intend the service to compete with existing manufacturers, especially those headquartered in China, and to attract biotech firms seeking faster, cost‑effective production solutions.